AHR and prostate carcinoma: Additionally, nimodipine (a calcium-channel blocker indicated for subarachnoid hemorrhage) and flutamide (an androgen receptor antagonist indicated for prostate cancer) for the first time were reported as compounds which competitively bind to the AhR in vitro [94].